PMID- 26894800
OWN - NLM
STAT- MEDLINE
DCOM- 20161025
LR  - 20221207
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Print)
IS  - 1173-2563 (Linking)
VI  - 36
IP  - 4
DP  - 2016 Apr
TI  - Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than 
      Either Insulin Degludec or Liraglutide Given Alone.
PG  - 293-303
LID - 10.1007/s40261-016-0376-0 [doi]
AB  - BACKGROUND AND OBJECTIVES: The time-course when changes in glycemic control and 
      body weight were first manifest in patients with type 2 diabetes mellitus (T2DM) 
      treated with a combination of insulin degludec and liraglutide (IDegLira) was 
      assessed, comparing IDegLira to its individual components. METHODS: Data from 
      weeks 0-12 from two studies were analyzed, one comparing IDegLira to each 
      component (DUAL I), and one comparing IDegLira to insulin degludec titrated to a 
      maximum 50 units (DUAL II). Efficacy endpoints included glycated hemoglobin 
      (HbA1c) and fasting plasma glucose (FPG) reduction, proportion of patients 
      achieving HbA1c [<7.0 % (<53.0 mmol/mol)] and FPG (</=7.2 mmol/L) targets, and 
      proportion achieving HbA1c target without hypoglycemia and without hypoglycemia 
      and weight gain. RESULTS: Mean HbA1c was lower, and the proportion of patients 
      reaching target HbA1c greater, with IDegLira versus comparators (both studies) at 
      weeks 8 and 12. Proportions of patients reaching target HbA1c without 
      hypoglycemia and without hypoglycemia and weight gain were higher for IDegLira 
      versus insulin degludec, though not versus liraglutide. Mean FPG was lower with 
      IDegLira, and the proportion achieving target FPG higher, versus components (both 
      studies) from weeks 4-12. IDegLira was associated with mean weight reduction from 
      weeks 4-12, although less than with liraglutide alone. Hypoglycemia occurred 
      infrequently in weeks 0-12, with no difference in incidence between IDegLira and 
      insulin degludec in either study. CONCLUSIONS: IDegLira reduces plasma glucose to 
      a greater extent than its components, measurable within the first 12 weeks of 
      therapy, and without weight gain or an increased hypoglycemia risk versus insulin 
      degludec.
FAU - Vilsboll, Tina
AU  - Vilsboll T
AD  - Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, 
      Hellerup, Denmark. t.vilsboll@dadlnet.dk.
FAU - Vora, Jiten
AU  - Vora J
AD  - Diabetes and Endocrinology, Royal Liverpool University Hospitals, Liverpool, UK.
FAU - Jarlov, Henrik
AU  - Jarlov H
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Kvist, Kajsa
AU  - Kvist K
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Blonde, Lawrence
AU  - Blonde L
AD  - Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Frank 
      Riddick Diabetes Institute, Ochsner Medical Center, New Orleans, LA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 54Q18076QB (insulin degludec)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Combinations
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/blood/chemically induced
MH  - Hypoglycemia/blood/chemically induced
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Insulin, Long-Acting/administration & dosage/adverse effects/*therapeutic use
MH  - Liraglutide/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Weight Gain
MH  - Weight Loss
PMC - PMC4801992
EDAT- 2016/02/20 06:00
MHDA- 2016/10/26 06:00
PMCR- 2016/02/19
CRDT- 2016/02/20 06:00
PHST- 2016/02/20 06:00 [entrez]
PHST- 2016/02/20 06:00 [pubmed]
PHST- 2016/10/26 06:00 [medline]
PHST- 2016/02/19 00:00 [pmc-release]
AID - 10.1007/s40261-016-0376-0 [pii]
AID - 376 [pii]
AID - 10.1007/s40261-016-0376-0 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2016 Apr;36(4):293-303. doi: 10.1007/s40261-016-0376-0.